<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR88502-0064 </DOCNO><DOCID>fr.5-02-88.f2.A1063</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="41">[Docket No. 88N-0157]</ITAG><ITAG tagnum="56">Drug Export; Genetic Systems HIV Antigen EIA and Genetic Systems HIVAntigen Neutralization Test Kits</ITAG><ITAG tagnum="10"><T2>AGENCY</T2>: Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION</T2>: Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY</T2>: The Food and Drug Administration (FDA) is announcingthat Genetic Systems has filed an application requesting approval for theexport of the biological products Genetics Systems HIV Antigen EIA andGenetic Systems HIV Antigen Neutralization Test kits to Australia.</ITAG><ITAG tagnum="10"><T2>ADDRESS</T2>: Relevant information on this application may be directedto the Dockets Management Branch (HFA-305), Food and Drug Administration,Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact personidentified below. Any future inquires concerning the export of human drugsunder the Drug Export Amendments Act of 1986 should also be directed tothe contact person.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT</T2>: Boyd Fogle, Jr., Center for BiologicsEvaluation and Research (HFN-322), Food and Drug Administration, 5600 FishersLane, Rockville, MD 20857, 301-295-8095.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION</T2>: The Drug Export Amendments Act of 1986(Pub. L. 99-660) (section 802 of the Federal Food, Drug, and Cosmetic Act(the act) (21 U.S.C. 382)) provides that FDA may approve applications forthe export of drugs that are not currently approved in the United States.The approval process is governed by section 802(b) of the act. Section802(b)(3)(B) of the act sets forth the requirements that must be met inan application for approval. Section 802(b)(3)(C) of the act requires thatthe agency review the application within 30 days of its filing to determinewhether the requirements of section 802(b)(3)(B) have been satisfied. Section802(b)(3)(A) of the act requires that the agency publish a notice in the<T4>Federal Register</T4> within 10 days of the filing of an applicationfor export to facilitate public participation in its review of the application.To meet this requirement, the agency is providing notice that Genetic Systems,3005 First Ave., Seattle, WA 98121, has filed an application requestingapproval for the export to Australia of the biological products GeneticSystems HIV Antigen EIA and Genetic Systems HIV Antigen NeutralizationTest kits. The Genetic Systems HIV Antigen EIA is an enzyme immunoassayfor the detection of HIV core antigen in cell culture specimens, serum,plasma, and cerebrospinal fluid. The Genetic Systems HIV Antigen NeutralizationTest is a test for the verification of HIV antigen-reactive samples detectedin the Genetic Systems HIV Antigen EIA. The application was received andfiled in the Center for Biologics Evaluation and Research on April 19,1988, which shall be considered the filing date for purposes of the act.Interested persons may submit relevant information on the application tothe Dockets Management Branch (address above) in two copies (except thatindividuals may submit single copies) and identified with the docket numberfound in brackets in the heading of this document. These submissions maybe seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Mondaythrough Friday.The agency encourages any person who submits relevant information on theapplication to do so by May 12, 1988, and to provide an additional copyof the submission directly to the contact person identified above, to facilitateconsideration of the information during the 30-day review period.This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec.802, Pub. L. 99-660 (21 U.S.C. 382)) and under authority delegated to theCommissioner of Food and Drugs (21 CFR 5.10) and redelegated under 21 CFR5.44.<ITAG tagnum="21">Dated: April 21, 1988.</ITAG><ITAG tagnum="6">Thomas S. Bozzo,</ITAG><ITAG tagnum="4">Director, Office of Compliance, Center for Biologics Evaluation andResearch.</ITAG><ITAG tagnum="40">[FR Doc. 88-9645 Filed 4-29-88; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>